Despite losing a $10 billion bid for Metsera to Pfizer, Novo Nordisk's CEO Mike Doustdar remains determined to pursue new opportunities in the obesity and diabetes sectors. The company aims to reclaim its position in the booming weight-loss market.
Eli Lilly & Co. and Novo Nordisk A/S have struck a deal with the Trump administration to lower prices for their popular weight-loss drugs, Zepbound and Wegovy, while gaining tariff relief and expanding Medicare access. This agreement aims to increase availability for older Americans.
A new report reveals that the U.S. adult obesity rate has declined to 37% in 2025, down from a record 39.9% in 2022, as more Americans turn to weight loss drugs like GLP-1 injectables. With 7.6 million fewer obese adults, is this the start of a healthier trend?
Eli Lilly's new obesity pill, orforglipron, faces tough competition but could disrupt the weight loss market. Despite underwhelming trial results, analysts see potential for success due to manufacturing advantages and pricing strategies.
Recent studies suggest a link between GLP-1 medications like Ozempic and vision loss. Learn about the risks and what you need to know if you're using these popular diabetes drugs.
Are you one of the many Americans using GLP-1 drugs like Ozempic or Wegovy? Discover essential lifestyle tips to prevent nutrient deficiencies and muscle loss while maximizing your weight loss results!
In a surprising move, Novo Nordisk CEO Lars Fruergaard Jorgensen steps down as the company faces significant market challenges and competition from Eli Lilly's Zepbound. With share prices plummeting, the board seeks new leadership to navigate the turbulent landscape.
In a groundbreaking clinical trial, Mounjaro proves to be nearly 50% more effective than Ozempic. This article explores the implications of this major breakthrough in weight loss treatments.
A landmark study reveals that weight-loss injections may significantly reduce the risk of obesity-related cancers, potentially transforming preventive medicine. The findings suggest that GLP-1 receptor agonists could halve cancer risk, prompting calls for further research.
A groundbreaking trial reveals that Mounjaro is more effective than Wegovy for weight loss, achieving a 20% reduction over 72 weeks compared to Wegovy's 14%. Discover the implications for obesity treatment!
